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Introduction
Head and neck squamous cell carcinoma (HNSCC) is
the 6th most common cancer in the world. In Taiwan, it
ranks 4th in male cancer-related death; in middle-age
male patients between 25 and 45 years old, the occur-
rence of oral cancer is the highest of all cancer occur-
rences.1 Most HNSCC patients in Taiwan are diagnosed
at a young age, with male predominance, and with
advanced disease. This unique patient population pro-
file may be related to the habitual consumption of cig-
arettes, alcohol, and betel nuts.2,3 Betel nut chewing
is a common habit among those who live in South Asia,
including Taiwan,4,5 and is an etiology of HNSCC.6
There are many compounds in the betel nut that have
been correlated with carcinogenesis; the habit of chew-
ing betel nut is related to persistent damage of the oral
mucosa as well as precancerous lesions such as leuko-
plakia and erythroplakia, and oral fibrosis.7 There is a
high level of carcinogenic nitrosamines in the saliva of
betel nut chewers, and the p53 gene mutation is cor-
related with the habit of betel nut chewing.7,8 In previ-
ous reports, overexpression of epidermal growth factor
receptor (EGFR) was found to be involved in betel
nut-related HNSCC.9,10
EGFR is a tyrosine kinase receptor belonging to the
ErbB family. This family includes 4 transmembrane
receptors: EGFR (erbB1), HER-2 (erbB2), HER-3
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(erbB3), and HER-4 (erbB4).11 These receptors inter-
act with each other by heterodimerization and result
in activation of intrinsic kinase activity.12 Overex-
pression of EGFR has been observed in a variety of
cancers such as lung, colorectal, and head and neck
cancers. The anti-EGFR monoclonal antibody cetux-
imab (Erbitux; Merck KGaA, Darmstadt, Germany),
which blocks dimerization, has been used to treat cer-
tain cancers with EGFR overexpression. In HNSCC,
cetuximab combined with radiotherapy has been
proven to have clinical benefit in primary treatment
for organ preservation.13 Phase II/III trials have also
been conducted to evaluate the efficacy and safety of
cetuximab-containing chemotherapy for recurrent/
metastatic HNSCC, and the results have shown better
response and prolonged survival compared with stan-
dard cisplatin-containing regimens.14–16 Since EGFR
overexpression is observed in HNSCC patients, espe-
cially in those who chew betel nut, the clinical benefit
of cetuximab-based therapy in betel-nut chewing areas
warrants a separate analysis.
For these reasons, we report here our experience
of cetuximab-based therapy in recurrent/metastatic
HNSCC patients, most of whom had a betel nut
chewing habit. Response, toxicity, and survival were
evaluated.
Methods
Patient population
We retrospectively analyzed 25 patients with recur-
rent/metastatic HNSCC who received cetuximab
alone or combined with chemotherapy in Taipei
Veterans General Hospital, Taiwan. Each patient
signed an informed consent form for cetuximab use
before treatment. Data used in our analyses were
delinked from the patients’ personal profiles. Exclusion
criteria were age ≤ 18 years old, Karnofsky perfor-
mance status ≤ 60%, inadequate hematologic, renal
and hepatic function before treatment, concomitant
malignancy, uncontrolled infection and any other sys-
temic diseases.
Definition of cisplatin failure
Cisplatin failure was defined as disease progression
within 6 months after the last course of cisplatin
administration.
Treatment plans
All patients received cetuximab as an intravenous
infusion at an initial dose of 400 mg/m2 followed by
250 mg/m2 every week. Concomitant chemotherapy
included cisplatin 100 mg/m2 every 3 weeks or 
docetaxel 80 mg/m2 every 3 weeks; or combination
therapy [cisplatin 75 mg/m2 or carboplatin (area under
the curve=4) on day 1 and 5-fluorouracil 1,000 mg/m2
on days 1–4 every 3 weeks; cisplatin 75mg/m2 on day 1
and docetaxel 75 mg/m2 or paclitaxel 150 mg/m2 on
day 1 every 3 weeks]. Treatment was continued until
disease progression, clinical deterioration, or the ap-
pearance of intolerable adverse effects.
Response and toxicity assessment
Treatment response was evaluated by the RECIST
criteria.17 Evaluation of response to treatment was
performed every 3 months. Toxicity was graded accord-
ing to the National Cancer Institute’s Common Toxicity
Criteria.18
Statistical analysis
All analyses were done using SPSS version 14.0 (SPSS
Inc., Chicago, IL, USA). Overall survival (OS) was
defined as the time from the start of cetuximab treat-
ment to the date of death or the date last seen. Time
to progression (TTP) was defined as the time from
the start of cetuximab treatment to the date of disease
progression or the date of the last follow-up. Median
and life tables were computed using the product-limit
estimate of the Kaplan-Meier method, and the log-
rank test was applied for the comparison of survival
periods between groups. The response analysis of each
clinical factor was compared using the χ2 or Fisher’s
exact test for categorical variables. Two-sided p values
less than 0.05 were considered statistically significant.
Results
Patient characteristics
From 2004 to 2008, 25 patients with recurrent/
metastatic HNSCC were enrolled in the study. There
were 23 male and 2 female patients; 15 (60%) had 
a betel nut chewing habit. The median follow-up
time was 370 days (range, 70–1,153 days). Thirteen
patients received first-line cetuximab plus chemother-
apy (77% were taxane-containing and 75% were cis-
platin-containing regimens; data not shown), and the
other 12 patients received second-line cetuximab-
based therapy (25% were cetuximab monotherapy and
75% were cetuximab combined with chemotherapy)
after cisplatin failure for recurrent/metastatic HNSCC.
The demographic characteristics of the 2 groups were
similar, with the exception of distant metastasis (67% vs.
23%, p = 0.003) and taxane-containing chemotherapy
(77% vs. 17%, p = 0.01) (Table 1).
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Treatment response
In the 13 patients who received first-line cetuximab-
based therapy as treatment for recurrent/metastatic
HNSCC, 3 (23%) achieved complete response (CR), 4
(31%) achieved partial response (PR) and 1 (8%) had sta-
ble disease (SD). The overall response rate to cetuximab-
based therapy as first-line treatment was 54%, and the
disease control rate was 62%. Among these 13 patients,
10 received taxane-containing regimens while 3 received
non-taxane-containing regimens. A trend of increased
complete response (30% vs. 0%) was observed in the
group who received taxane-containing regimens. The
response profile of using cetuximab-containing regimen
as first-line therapy for recurrent/metastatic HNSCC
is shown in Table 2.
Twelve patients received cetuximab as second-line
therapy after the failure of cisplatin treatment. One
(8.3%) patient with CR, 1 (8.3%) with PR, and 4
(33.3%) with SD were observed. The overall response
and disease control rates were 16.7% and 50%, respec-
tively. Among these 12 patients, 3 (25%) received cetux-
imab monotherapy; only 1 (33.3%) PR was observed,
with no CR or SD. The other 9 patients who received
cetuximab combined with chemotherapy showed 1 CR
(11.1%) and 4 SD (44.4%). The disease control rate
was better in the cetuximab plus chemotherapy group
Table 1. Characteristics of the 25 patients who received cetuximab-based therapy for recurrent/metastatic head and neck squamous
cell carcinoma*
First-line cetuximab + chemotherapy (n = 13) Cisplatin-failure chemotherapy (n = 12) p
Age 54 (36–81) 58 (43–76) 0.42
Sex 0.95
Male 12 (92.3) 11 (92)
Female 1 (7.7) 1 (8)
Betel nut chewing 0.69
Yes 7 (54) 8 (67)
No 6 (46) 4 (33)
Primary site 0.80
Oral cavity 3 (23) 2 (17)
Oropharynx 1 (8) 1 (8)
Hypopharynx 3 (23) 5 (42)
Larynx 2 (15) 1 (8)
Unknown primary 4 (31) 3 (25)
Recurrent/metastatic sites 0.003
Local recurrence 8 (62) 1 (8)
Lung metastasis 2 (15) 3 (25)
Multiple metastases 3 (23) 8 (67)
Combined chemotherapy 0.01
Taxane-containing 10 (77) 2 (17)
Non-taxane-containing 3 (23) 7 (58)
Without combination 0 (0) 3 (25)
Cetuximab cycles 6 (1–12) 5 (1–11) 0.59
*Data presented as median (range) or n (%).
Table 2. Responses of the 13 patients to first-line cetuximab plus chemotherapy for recurrent/metastatic head and neck squamous
cell carcinoma*
Taxane-containing (n = 10) Non-taxane-containing (n = 3) p Overall (n = 13)
CR 3 (30) 0 (0) 0.28 3 (23)
PR 2 (20) 2 (66.7) 0.13 4 (31)
SD 1 (10) 0 (0) 0.57 1 (8)
PD 4 (40) 1 (33.3) 0.84 5 (38)
*Data presented as n (%). CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease.
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than in the cetuximab monotherapy group (55.6% vs.
33.3%). The results of using cetuximab-based therapy
as second-line treatment after cisplatin failure are
shown in Table 3.
To identify the predictors of treatment response,
several clinical factors were analyzed in all 25 patients.
Only cisplatin status showed a significant difference in
overall response (54% vs. 16.7%, p = 0.05) (Table 4).
Survival analysis
In the 13 patients who received first-line chemother-
apy for recurrent/metastatic HNSCC, median OS
and TTP were 857 days and 147 days, respectively
(Figures 1 and 2). In the 12 patients who received
chemotherapy for cisplatin-failure recurrent/metasta-
tic HNSCC, median OS was 371 days and median
TTP was 136 days (Figures 1 and 2). Betel nut chew-
ing status and survival were evaluated: the OS of
patients who chewed and those who did not chew
betel nut were 371 days and 493 days (p = 0.34),
respectively, and the TTPs were 135 days and 154
days (p = 0.54), respectively (Figures 3 and 4).
Table 3. Responses of the 12 patients to cisplatin-failure chemotherapy for recurrent/metastatic head and neck squamous cell 
carcinoma*
Cetuximab monotherapy (n = 3) Cetuximab combination chemotherapy (n = 9) p Overall (n = 12)
CR 0 (0) 1 (11.1) 0.55 1 (8.3)
PR 1 (33.3) 0 (0) 0.07 1 (8.3)
SD 0 (0) 4 (44.4) 0.16 4 (33.3)
PD 2 (66.7) 4 (44.4) 0.51 6 (50.0)
*Data presented as n (%). CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease.
Table 4. Responses of patients with different clinical characteristics to treatment for recurrent/metastatic head and neck squamous
cell carcinoma*
CR + PR p CR + PR + SD p
Betel nut chewing habit 0.73 0.74
Yes 5 (33) 8 (53)
No 4 (40) 6 (60)
Platinum status 0.05 0.56
Cisplatin failure 2 (20) 6 (50)
No cisplatin failure 7 (54) 8 (62)
Taxane 0.16 0.82
Yes 6 (50) 7 (54)
No 3 (23) 3 (23)
Cetuximab 0.62 0.17
With chemotherapy 8 (38) 13 (62)
Without chemotherapy 1 (25) 1 (25)
*Data presented as n (%). CR = complete response; PR = partial response; SD = stable disease.
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Figure 1. Kaplan-Meier overall survival curves for patients with
recurrent/metastatic head and neck squamous cell carcinoma
who received first-line or cisplatin-failure cetuximab chemother-
apy (median, 857 days vs. 371 days; p = 0.167).
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Figure 2. Kaplan-Meier time-to-progression curves for patients
with recurrent/metastatic head and neck squamous cell carci-
noma who received first-line or cisplatin-failure cetuximab
chemotherapy (median, 147 days vs. 136 days; p = 0.48).
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Figure 3. Kaplan-Meier overall survival curves for patients with
recurrent/metastatic head and neck squamous cell carcinoma
who have or do not have a betel nut chewing habit (median, 371
days vs. 493 days; p = 0.34).
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Figure 4. Kaplan-Meier time-to-progression curves for patients
with recurrent/metastatic head and neck squamous cell carci-
noma who have or do not have a betel nut chewing habit (median,
135 days vs. 154 days; p = 0.54).
Toxicity
We analyzed the toxicities of cetuximab and chemother-
apy together. As shown in Table 5, the most common
grade 3/4 toxicities with first-line cetuximab-based
therapy were infection/fever (23%) and neutropenia
(23%). Other grade 3/4 toxicities included mucositis/
stomatitis (8%), dysphagia (8%), and acne-like rash (8%).
With second-line cetuximab-based therapy, the most
common toxicity was infection/fever (50%), followed
by neutropenia (25%), anemia (16.7%), thrombocy-
topenia (8.3%), dysphagia (8.3%), weight loss (8.3%),
and acne-like rash (8.3%).
Discussion
In this study, we demonstrated that cetuximab-based
chemotherapy increased the response and survival in
patients with recurrent/metastatic HNSCC in an area
where betel nut chewing is popular. The prognosis of
recurrent/metastatic HNSCC has been poor. Even
with cisplatin-containing chemotherapy, the objective
maximal response rate that could be achieved was about
30%, and OS was around 6–9 months.19–23 In a recent
phase III trial, adding cetuximab to first-line cisplatin-
based chemotherapy for the treatment of recurrent/
metastatic HNSCC significantly improved the res-
ponse to about 40% and OS to 10 months.16 As the
first representative results from an area where betel nut
chewing is popular, our findings are consistent with
those of the previous large-scale study.16 It is interest-
ing to note that betel nut chewing does not seem to be
related to poor response and survival (Figures 3 and 4).
A possible explanation is that most patients with a betel
nut chewing habit have a higher EGFR gene copy
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number,9 which is thought to be a determining factor
of the response to cetuximab treatment.24 This expla-
nation, however, needs further studies for verification.
A significant proportion of patients (48%) in this
study accepted taxane-containing chemotherapy. The
major consideration to add taxane to chemotherapy
regimens is that taxane is an effective chemotherapy in
HNSCC and in combination with platinum; it shows
better therapeutic effects than conventional cisplatin/5-
fluorouracil regimens.25–27 Although the results of the
current study are preliminary and the case number was
relatively small, taxane-containing chemotherapy
seemed to lead to a better response than non-taxane
chemotherapy (overall response rate, 50% vs. 23%;
disease control rate, 54% vs. 23%), especially for the
first-line cases (CR, 30% vs. 0%; Table 2). The combina-
tion of cetuximab and taxane is well-tolerated. There
are ongoing trials to determine the effect of combining
these 2 agents in the treatment of HNSCC.28,29 How-
ever, large-scale pivotal studies are warranted to con-
firm the efficacy and safety.
The prognosis in patients after cisplatin failure is par-
ticularly poor, and response rates are generally < 5%.30
Some phase II trials have explored the possible role of
cetuximab alone or in combination with a platinum
compound.14,15 The results suggest that combined
cetuximab and platinum-based chemotherapy is an
active and well-tolerated treatment choice. In previous
reports, cetuximab did not increase the toxicity of com-
bined chemotherapy, and there did not appear to be any
difference in response between single-agent and com-
bination cetuximab therapy.14,15,31 Vermorken et al
summarized 3 previous prospective studies of second-
line cetuximab treatment of recurrent/metastatic
HNSCC after cisplatin failure and reported an overall
response rate of 10–13%, and a disease control rate of
46–56%.32 Haddad and Shin summarized 3 other
prospective studies of first-line combination cetuximab
therapy for recurrent/metastatic HNSCC and reported
an overall response rate of 26.3–35.6%, and OS of
9.2–10.4 months.33 In the current study, cetuximab
combined with chemotherapy seemed to result in better
response than cetuximab monotherapy (disease control
rate, 56% vs. 33%). A possible explanation is that 2
(17%) patients accepted taxane-containing chemother-
apy, and 1 (8%) achieved CR while 1 (8%) had SD.
There was an interesting observation that TTP was
almost the same in the first-line chemotherapy and cis-
platin-failure therapy groups (147/136 days). A pos-
sible explanation is that in the 1st treatment arm of the
study population, there were 2 patient subgroups, which
were those with controlled disease versus those with
uncontrolled disease. The patients with controlled dis-
ease had much better survival than the patients with
uncontrolled disease (due to the still high response to
second-line cisplatin-failure chemotherapy), and such a
phenomenon could explain why similar TTPs were
observed. However, it was difficult to further analyze
the data due to the very small patient numbers.
With regard to toxicity profile, there were no addi-
tive toxicities when we compared the 22 patients who
received combination therapies with the 3 patients who
received cetuximab monotherapy. This finding is com-
patible with that of previous studies. Since the incidence
of grade 3/4 toxicity did not increase significantly
(infection/fever, 50% in combination therapy vs. 66.7%
in monotherapy, data not shown), using taxanes rather
than platinum combined with cetuximab in platinum-
failure HNSCC could be considered in patients with
good performance status.
Table 5. Common toxicities in the 25 patients who received cetuximab-based therapy for recurrent/metastatic head and neck 
squamous cell carcinoma*
First-line cetuximab + chemotherapy (n = 13) Cisplatin-failure chemotherapy (n = 12)
NCICTC grade 3–4 3–4
Mucositis/stomatitis 1 (8) 0 (0)
Dysphagia 1 (8) 1 (8.3)
Nausea 0 (0) 0 (0)
Vomiting 0 (0) 0 (0)
Diarrhea/constipation 0 (0) 0 (0)
Infection/fever 3 (23) 6 (50.0)
Weight loss 0 (0) 1 (8.3)
Neutropenia 3 (23) 3 (25.0)
Anemia 0 (0) 2 (16.7)
Thrombocytopenia 0 (0) 1 (8.3)
Acne-like rash 1 (8) 1 (8.3)
*Data presented as n (%) except for NCICTC grade. NCICTC = National Cancer Institute Common Toxicity Criteria.
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In conclusion, our report is the first to demon-
strate the efficacy and safety of using cetuximab-based
therapy in recurrent/metastatic HNSCC from an
area where betel nut chewing is popular. We also
showed the efficacy and safety of combining cetux-
imab with taxanes in recurrent/metastatic HNSCC,
both in first-line and platinum failure settings. Fur-
ther large-scale trials are warranted to confirm these
observations.
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